Arnab Chakravarti

Arnab Chakravarti, MD

  • Radiation Oncology
  • Physician

Insurances We Accept

614-293-8415

About Me

I am professor and chair of the Department of Radiation Oncology at The Ohio State University, where I also hold the Max Morehouse Chair of Cancer Research and direct the Brain Tumor Program. I was named to the Castle Connolly list of “America's Top Doctors” from 2012-2019.

A member of the Translational Therapeutics Program at the OSUCCC – James, I focus on translational cancer research to identify novel biomarkers that are predictive of treatment efficacy and survival, and to uncover molecular and genetic mechanisms of treatment resistance to advance care of cancer patients. Under my leadership with the National Cancer Institute-supported Radiation Therapy and Oncology Group Brain Tumor/NRG Translational Research Subcommittee and Brain Tumor Committee, my team’s studies have defined the standard of care for patients with central nervous system (CNS) tumors.

My lab was among the first to report that the dysregulation of PI3K/AKT signaling is associated with radiation resistance in glioblastomas. It also was the first to identify that dysregulation of PI3K signaling is significantly associated with adverse clinical outcomes in GBM patients. These findings led to some of the first clinical studies to combine radiotherapy with kinase inhibitors targeting this pathway.

Additionally, I have published more than 120 articles in leading scientific and medical journals, including The New England Journal of Medicine, Journal of the American Medical Association, Cancer Cell and Journal of Clinical Oncology. I have delivered numerous distinguished lectureships in the United States, Asia and Europe on cutting-edge therapies for cancer patients and have received more than two dozen national and international awards for outstanding clinical care and landmark research accomplishments.

My approach is to personalize cancer care by investigating strategies that are most effective to individual patients through genetic and molecular profiling instead of using the “one glove fits all” approach that is more commonly used in cancer care. In Ohio State’s cancer program, we appreciate that every patient is unique and requires targeted strategies for optimal personalized care.
Highlights
  • Named to the Castle Connolly list of “America's Top Doctors,” 2012–2019; "America's Top Doctors for Cancer," 2012–2019
  • Best Doctor in America, 2017

Procedures and Conditions I Treat

  • Brain Cancers
  • Leukemia
  • Lymphomas
  • Radiosurgery
  • Central Nervous System Tumors
  • Neuroectodermal Tumors, Primitive
  • Astrocytoma
  • Optic Nerve Glioma
  • Gliosarcoma
  • Oligodendroglioma
  • Ganglioglioma
  • ACTH-Secreting Pituitary Adenoma
  • Pituitary Irradiation
  • Meningioma
  • Cerebellar Cancers
  • Spinal Cord Tumors
  • Spine Sarcoma
  • Radiation Oncology
  • Cranial Irradiation
  • Ganglioneuroma
  • Brain Stem Tumor

Education and Training

Education History

Medical School

University of Virginia School of Medicine, Charlottesville, VA
MD
8/26/1991 - 5/21/1995

Internship

Harvard Medical School, Boston, MA

6/1/1995 - 6/30/1996

Residency

Massachusetts General Hospital, Boston, MA

7/1/1996 - 6/30/1999

Residency

Massachusetts General Hospital, Boston, MA

7/1/1999 - 6/30/2000

Board Certification

American Board of Radiology (Subspecialty: Radiation Oncology)
11/6/2000

Academic Information

My Department

Radiation Oncology

More About My Work

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.

As of 11/21/2019, Dr. Chakravarti has reported no relationships with companies or entities.